ConductScience.org, home
Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension
API referenceFor AI assistants

Trial · NCT02207621

Adverse events168

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

101 to 120 of 168

Download this page as JSON
TypeEventOrgan systemGroupAffectedAt riskEvents
seriousCerebrovascular AccidentNervous system disordersTimolol Maleate Ophthalmic Solution 0.5% BID0251
seriousCerebrovascular AccidentNervous system disordersAR-13324 Ophthalmic Solution 0.02% BID0253
seriousEmbolic StrokeNervous system disordersAR-13324 Ophthalmic Solution 0.02% & Placebo1251
seriousEmbolic StrokeNervous system disordersTimolol Maleate Ophthalmic Solution 0.5% BID0251
seriousEmbolic StrokeNervous system disordersAR-13324 Ophthalmic Solution 0.02% BID0253
seriousCarotid Artery StenosisNervous system disordersAR-13324 Ophthalmic Solution 0.02% & Placebo0251
seriousCarotid Artery StenosisNervous system disordersTimolol Maleate Ophthalmic Solution 0.5% BID1251
seriousCarotid Artery StenosisNervous system disordersAR-13324 Ophthalmic Solution 0.02% BID0253
seriousEpistaxisRespiratory, thoracic and mediastinal disordersAR-13324 Ophthalmic Solution 0.02% & Placebo0251
seriousEpistaxisRespiratory, thoracic and mediastinal disordersTimolol Maleate Ophthalmic Solution 0.5% BID0251
seriousEpistaxisRespiratory, thoracic and mediastinal disordersAR-13324 Ophthalmic Solution 0.02% BID1253
seriousPulmonary Artery StenosisRespiratory, thoracic and mediastinal disordersAR-13324 Ophthalmic Solution 0.02% & Placebo1251
seriousPulmonary Artery StenosisRespiratory, thoracic and mediastinal disordersTimolol Maleate Ophthalmic Solution 0.5% BID0251
seriousPulmonary Artery StenosisRespiratory, thoracic and mediastinal disordersAR-13324 Ophthalmic Solution 0.02% BID0253
seriousPulmonary EmbolismRespiratory, thoracic and mediastinal disordersAR-13324 Ophthalmic Solution 0.02% & Placebo0251
seriousPulmonary EmbolismRespiratory, thoracic and mediastinal disordersTimolol Maleate Ophthalmic Solution 0.5% BID1251
seriousPulmonary EmbolismRespiratory, thoracic and mediastinal disordersAR-13324 Ophthalmic Solution 0.02% BID0253
seriousAccelerated HypertensionVascular disordersAR-13324 Ophthalmic Solution 0.02% & Placebo1251
seriousAccelerated HypertensionVascular disordersTimolol Maleate Ophthalmic Solution 0.5% BID0251
seriousAccelerated HypertensionVascular disordersAR-13324 Ophthalmic Solution 0.02% BID0253

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Previous pageNext page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02207621/events?page=6

API referenceFor AI assistants